RxDoctor Payments Data

Greg Smart, MD

Family Medicine · El Dorado, ARNPI 1073506010

Payments from drug & device makers

$257in general payments, 2019–2025

Across 15 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$63
  • Novo Nordisk$42
  • Lilly USA, LLC$36
  • AbbVie$34
  • Abbott$28
  • Novartis$28
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$257100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca2$63
Novo Nordisk3$42
Lilly USA, LLC2$36
AbbVie2$34
Abbott2$28
Novartis2$28
Amgen1$14
GSK1$13

How this compares

$257 in reported general payments places this provider in the 35th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$295,117
Medicare patients
633
Services billed
4,199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban474$182,078
JardianceEmpagliflozin102$59,207
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog47$41,413
XareltoRivaroxaban93$35,448
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$32,082
TivicayDolutegravir Sodium12$28,320
DescovyEmtricitabine/Tenofov Alafenam12$27,629
EntrestoSacubitril/Valsartan61$22,065
Tresiba Flextouch U-100Insulin Degludec17$19,289
FarxigaDapagliflozin Propanediol31$17,688
OzempicSemaglutide15$15,994
Janumet XrSitagliptin Phos/Metformin Hcl23$15,292
GemtesaVibegron48$14,120
Potassium Chloride488$12,901
Sucralfate80$12,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$13$48,53782 claims
AstraZenecaFarxiga, Brilinta$63$29,85363 claims
NovartisEntresto$28$22,06561 claims
Novo NordiskOzempic$42$15,99415 claims
AbbVieLumigan$34$3,88413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in El Dorado

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →